# A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

> **NCT01424813** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 158 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Placebo MDPI
- **DRUG:** Albuterol MDPI

## Key facts

- **NCT ID:** NCT01424813
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-10
- **Final completion:** 2013-11
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2015-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01424813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01424813, "A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01424813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*